Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective—: Triglyceride-rich lipoproteins have emerged as causal risk factors for developing coronary heart disease independent of low-density lipoprotein cholesterol levels. Apolipoprotein C-III (ApoC-III) modulates triglyceride-rich lipoprotein metabolism through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. Mutations causing loss-of-function of ApoC-III lower triglycerides and reduce coronary heart disease risk, suggestive of a causal role for ApoC-III. Little data exist about the relationship of ApoC-III, triglycerides, and atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Here, we examined the relationships between plasma ApoC-III, triglycerides, and coronary artery calcification in patients with T2DM. Approach and Results—: Plasma ApoC-III levels were measured in a cross-sectional study of 1422 subjects with T2DM but without clinically manifest coronary heart disease. ApoC-III levels were positively associated with total cholesterol (Spearman r =0.36), triglycerides ( r =0.59), low-density lipoprotein cholesterol ( r =0.16), fasting glucose ( r =0.16), and glycosylated hemoglobin ( r =0.12; P <0.0001 for all). In age, sex, and race-adjusted analysis, ApoC-III levels were positively associated with coronary artery calcification (Tobit regression ratio, 1.78; 95% confidence interval, 1.27–2.50 per SD increase in ApoC-III; P <0.001). As expected for an intermediate mediator, these findings were attenuated when adjusted for both triglycerides (Tobit regression ratio, 1.43; 95% confidence interval, 0.94–2.18; P =0.086) and separately for very low–density lipoprotein cholesterol (Tobit regression ratio, 1.14; 95% confidence interval, 0.75–1.71; P =0.53). Conclusions—: In persons with T2DM, increased plasma ApoC-III is associated with higher triglycerides, less favorable cardiometabolic phenotypes, and higher coronary artery calcification, a measure of subclinical atherosclerosis. Therapeutic inhibition of ApoC-III may thus be a novel strategy for reducing plasma triglyceride-rich lipoproteins and cardiovascular risk in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989 · cited 1×
“It has been previously shown that CAC scores >100 robustly predict risk of coronary events in patients >7-fold relative to no CAC, as per the Agatston scoring criteria for CAC, and this relationship is consistent across different ethnicities.(32) We found that when we separated subjects in our study by”
ResultNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Common variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862 · cited 2×
“Among the genes implicated in these studies is APOC3, which encodes apolipoprotein C-III (ApoC-III).(4,6,7) ApoC-III is a small protein (8.”
Self-citationBoekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 2×
“One previous genotyping study of an APOC3 variant in the Lancaster Amish and 2 recent sequencing studies in large populations identified loss-of-function variants in APOC3 that were associated with lower plasma triglycerides and reduced CAD risk.(6,7,19) These 3 studies have established a direct casual genetic role fo…”
BackgroundExome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
Self-citationImpact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression
Puri, R., Nicholls, S. J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S. R., Tuzcu, E. M., & Nissen, S. E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.036 · Cited by 571
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · cited 1×
“At least 1 therapy targeting ApoC-III, antisense oligonucleotides silencing hepatic APOC3 expression, is in clinical development.(47) Recently, this therapy was shown to successfully reduce ApoC-III levels and plasma triglycerides in 3 patients with familial chylomicronemia syndrome, a genetic cause of profoundly elev…”
BackgroundApolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · cited 1×
“8 kDa) that is secreted from the liver and small intestine.(11) ApoC-III circulates in the blood on very LDLs (VLDLs), chylomicrons, and high-density lipoproteins (HDLs).”
BackgroundLi, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · cited 1×
“Recent human genetics studies have given credence to the concept that triglyceride-rich lipoproteins (TRLs) may be causally related to cardiovascular risk.(4,5) Genetic variation in several genes in the lipoprotein lipase pathway of plasma triglyceride hydrolysis is associated with triglyceride levels and CHD risk.”
BackgroundLipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Rip, J., Nierman, M. C., Ross, C. J., Jukema, J. W., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., & Kuivenhoven, J. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219283.10832.43 · Cited by 157
Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00025-x · Cited by 134
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50
Cited by
Highlighting Diabetes Mellitus: The Epidemic Continues
Schmidt, A. M. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310221 · Cited by 292
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135
“It is known that TG-metabolism plays a central role in CVD risk [31] and higher TG levels in T2DM subjects are associated with less favorable cardio-metabolic phenotypes and subclinical atherosclerosis [32], that may lead to increased CVD mortality [33].”
Background
Metadata
- Authors
- Qamar, A., Khetarpal, S. A., Khera, A. V., Qasim, A., Rader, D. J., & Reilly, M. P.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2015-08
- Volume
- 35
- Issue
- 8
- Pages
- 1880-1888
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2123644569
- Cited by
- 76
- References
- 19
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.